{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T12:14:46Z","timestamp":1792671286518,"version":"4.5.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T00:00:00Z","timestamp":1698710400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","canadianjournalofophthalmology.ca","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Ophthalmology"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.jcjo.2023.10.017","type":"journal-article","created":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T16:05:23Z","timestamp":1700323523000},"page":"350-357","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Long-term effect of fluid volumes during the maintenance phase in neovascular age-related macular degeneration: results from Fight Retinal Blindness!"],"prefix":"10.1016","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7661-4015","authenticated-orcid":false,"given":"Gregor S.","family":"Reiter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6127-6770","authenticated-orcid":false,"given":"Virginia","family":"Mares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Leingang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Fuchs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hrvoje","family":"Bogunovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5431-4991","authenticated-orcid":false,"given":"Daniel","family":"Barthelmes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"Schmidt-Erfurth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcjo.2023.10.017_bib0001","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1136\/bjophthalmol-2017-311258","article-title":"Prevalence and causes of vision loss in high-income countries and in Eastern and Central Europe in 2015: magnitude, temporal trends and projections","volume":"102","author":"Bourne","year":"2018","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jcjo.2023.10.017_bib0002","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","article-title":"Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"396","author":"Abbafati","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jcjo.2023.10.017_bib0003","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/S0140-6736(22)02609-5","article-title":"Age-related macular degeneration","volume":"401","author":"Guymer","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jcjo.2023.10.017_bib0004","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1136\/bjophthalmol-2014-305702","article-title":"Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA)","volume":"98","author":"Schmidt-Erfurth","year":"2014","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jcjo.2023.10.017_bib0005","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.ophtha.2019.11.004","article-title":"Consensus nomenclature for reporting neovascular age-related macular degeneration data","volume":"127","author":"Spaide","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2023.10.017_bib0006","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/j.ophtha.2016.03.045","article-title":"Five-year outcomes with anti\u2013vascular endothelial growth factor treatment of neovascular age-related macular degeneration","volume":"123","author":"Maguire","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2023.10.017_bib0007","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.oret.2019.05.017","article-title":"Visual acuity outcomes and anti\u2013vascular endothelial growth factor therapy intensity in neovascular age-related macular degeneration patients","volume":"4","author":"Ciulla","year":"2020","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.jcjo.2023.10.017_bib0008","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.oret.2019.09.009","article-title":"SIERRA-AMD: a retrospective, real-world evidence study of patients with neovascular age-related macular degeneration in the United States","volume":"4","author":"Khanani","year":"2020","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.jcjo.2023.10.017_bib0009","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1038\/s41433-020-01354-4","article-title":"Impact of macular fluid volume fluctuations on visual acuity during anti-VEGF therapy in eyes with nAMD","volume":"35","author":"Chakravarthy","year":"2021","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.jcjo.2023.10.017_bib0010","article-title":"Quantitative assessment of retinal fluid in neovascular age-related macular degeneration under anti-VEGF therapy","volume":"14","author":"Reiter","year":"2022","journal-title":"Ther Adv Ophthalmol"},{"key":"10.1016\/j.jcjo.2023.10.017_bib0011","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.ophtha.2017.10.031","article-title":"Fully automated detection and quantification of macular fluid in OCT using deep learning","volume":"125","author":"Schlegl","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2023.10.017_bib0012","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1038\/s41433-022-02077-4","article-title":"Therapeutic response in the HAWK and HARRIER trials using deep learning in retinal fluid volume and compartment analysis","volume":"37","author":"Schmidt-Erfurth","year":"2023","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.jcjo.2023.10.017_bib0013","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/j.ophtha.2020.03.010","article-title":"Application of automated quantification of fluid volumes to anti-VEGF therapy of neovascular age-related macular degeneration","volume":"127","author":"Schmidt-Erfurth","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2023.10.017_bib0014","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1038\/s41591-018-0107-6","article-title":"Clinically applicable deep learning for diagnosis and referral in retinal disease","volume":"24","author":"De Fauw","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.jcjo.2023.10.017_bib0015","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.3389\/fmed.2022.958469","article-title":"Predicting treat-and-extend outcomes and treatment intervals in neovascular age-related macular degeneration from retinal optical coherence tomography using artificial intelligence","volume":"9","author":"Bogunovi\u0107","year":"2022","journal-title":"Front Med"},{"key":"10.1016\/j.jcjo.2023.10.017_bib0016","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.ophtha.2015.12.002","article-title":"Macular morphology and visual acuity in the second year of the Comparison of Age-Related Macular Degeneration Treatments Trials","volume":"123","author":"Sharma","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2023.10.017_bib0017","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.preteyeres.2015.07.007","article-title":"A paradigm shift in imaging biomarkers in neovascular age-related macular degeneration","volume":"50","author":"Schmidt-Erfurth","year":"2016","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.jcjo.2023.10.017_bib0018","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/ceo.13949","article-title":"Neovascular age-related macular degeneration: a review of findings from the real-world Fight Retinal Blindness! Registry","volume":"49","author":"Nguyen","year":"2021","journal-title":"Clin Exp Ophthalmol"},{"key":"10.1016\/j.jcjo.2023.10.017_bib0019","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1097\/IAE.0000000000003557","article-title":"Validation of an automated fluid algorithm on real-world data of neovascular age-related macular degeneration over five years","volume":"42","author":"Gerendas","year":"2022","journal-title":"Retina"},{"key":"10.1016\/j.jcjo.2023.10.017_bib0020","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1097\/IAE.0000000000003023","article-title":"Analysis of fluid volume and its impact on visual acuity in the FLUID study as quantified with deep learning","volume":"41","author":"Reiter","year":"2021","journal-title":"Retina"},{"key":"10.1016\/j.jcjo.2023.10.017_bib0021","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1097\/IAE.0000000000003180","article-title":"Impact of residual subretinal fluid volumes on treatment outcomes in a subretinal fluid\u2013tolerant treat-and-extend regimen","volume":"41","author":"Grechenig","year":"2021","journal-title":"Retina"},{"key":"10.1016\/j.jcjo.2023.10.017_bib0022","article-title":"Approved AI-based fluid monitoring to identify morphological and functional treatment outcomes in neovascular age-related macular degeneration in real-world routine (FRB!)","author":"Mares","year":"2023","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jcjo.2023.10.017_bib0023","doi-asserted-by":"crossref","first-page":"OCT14","DOI":"10.1167\/iovs.16-19969","article-title":"Optical coherence tomography and the development of antiangiogenic therapies in neovascular age-related macular degeneration","volume":"57","author":"Rosenfeld","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jcjo.2023.10.017_bib0024","article-title":"Artificial intelligence\u2013based fluid quantification and associated visual outcomes in a real-world, multicentre neovascular age-related macular degeneration national database","volume":"0","author":"Martin-Pinardel","year":"2023","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jcjo.2023.10.017_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2023.100319","article-title":"Machine learning to predict response to ranibizumab in neovascular age-related macular degeneration","volume":"3","author":"Maunz","year":"2023","journal-title":"Ophthalmol Sci"},{"key":"10.1016\/j.jcjo.2023.10.017_bib0026","article-title":"Applications of artificial intelligence and bioinformatics methodologies in the analysis of ocular biofluid markers: a scoping review","volume":"10","author":"Pucchio","year":"2023","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jcjo.2023.10.017_bib0027","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12886-016-0207-3","article-title":"The role of sub-retinal fluid in determining treatment outcomes in patients with neovascular age-related macular degeneration\u2014a phase IV randomised clinical trial with ranibizumab: The FLUID study","volume":"16","author":"Arnold","year":"2016","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.jcjo.2023.10.017_bib0028","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ophtha.2018.11.025","article-title":"Tolerating subretinal fluid in neovascular age-related macular degeneration treated with ranibizumab using a treat-and-extend regimen","volume":"126","author":"Guymer","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2023.10.017_bib0029","doi-asserted-by":"crossref","DOI":"10.1111\/aos.14905","article-title":"The role of retinal fluid location in atrophy and fibrosis evolution of patients with neovascular age-related macular degeneration long-term treated in real world","volume":"100","author":"Llorente-Gonz\u00e1lez","year":"2022","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.jcjo.2023.10.017_bib0030","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jcjo.2021.04.020","article-title":"Longitudinal assessment of type 3 macular neovascularization using 3D volume-rendering OCTA","volume":"57","author":"Borrelli","year":"2022","journal-title":"Can J Ophthalmol"},{"key":"10.1016\/j.jcjo.2023.10.017_bib0031","first-page":"1","article-title":"Characterisation of macular neovascularisation subtypes in age-related macular degeneration to optimise treatment outcomes","volume":"2022","author":"Mathis","year":"2022","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.jcjo.2023.10.017_bib0032","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1167\/iovs.63.11.4","article-title":"The fovea-protective impact of double-layer sign in eyes with foveal-sparing geographic atrophy and age-related macular degeneration","volume":"63","author":"Fukuyama","year":"2022","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jcjo.2023.10.017_bib0033","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1159\/000499719","article-title":"One-year results of fixed aflibercept treatment regime in type 3 neovascularization","volume":"243","author":"Ernest","year":"2020","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.jcjo.2023.10.017_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2021.100972","article-title":"AI-based monitoring of retinal fluid in disease activity and under therapy","volume":"86","author":"Schmidt-Erfurth","year":"2022","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.jcjo.2023.10.017_bib0035","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1038\/s41433-022-02154-8","article-title":"Personalized treatment supported by automated quantitative fluid analysis in active neovascular age-related macular degeneration (nAMD)\u2014a phase III, prospective, multicentre, randomized study: design and methods","volume":"37","author":"Coulibaly","year":"2023","journal-title":"Eye (Lond)"}],"container-title":["Canadian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008418223003356?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008418223003356?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,17]],"date-time":"2024-09-17T13:50:54Z","timestamp":1726581054000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0008418223003356"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S0008418223003356"],"URL":"https:\/\/doi.org\/10.1016\/j.jcjo.2023.10.017","relation":{},"ISSN":["0008-4182"],"issn-type":[{"value":"0008-4182","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term effect of fluid volumes during the maintenance phase in neovascular age-related macular degeneration: results from Fight Retinal Blindness!","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcjo.2023.10.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Inc. on behalf of Canadian Ophthalmological Society.","name":"copyright","label":"Copyright"}]}}